|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Adenosine#Adult Indications and Dosage]] |
| {{Adenosine}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| Intravenous Adenocard (adenosine injection) is indicated for the following.
| |
| | |
| Conversion to sinus rhythm of [[paroxysmal supraventricular tachycardia]] (PSVT), including that associated with accessory bypass tracts ([[Wolff-Parkinson-White Syndrome]]). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to Adenocard administration.
| |
| | |
| It is important to be sure the Adenocard solution actually reaches the systemic circulation (see Dosage and Administration).
| |
| | |
| Adenocard does not convert atrial flutter, [[atrial fibrillation]], or ventricular [[tachycardia]] to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following Adenocard administration.
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ADENOCARD (ADENOSINE) SOLUTION [ASTELLAS PHARMA US, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0e32589-dad9-4887-8481-bcf7f6618466 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]]
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Drugs]]
| |
| [[Category:Antiarrhythmic agents]]
| |